Ascentage Pharma Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ascentage Pharma Group (AAPG).

Price Target Range — 5 Quarters

Analyst Consensus — 9 Analysts

1S.Buy

8Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$45Upside to Avg. PT+207.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 14, 2026	Citigroup	Yigal Nochomovitz	Initiate	Buy	$46
Oct 13, 2026	Citizens	Silvan Turkcan	Initiate	Market Outperform	$35
Oct 8, 2026	JP Morgan	Brian Cheng	PT Cut	Overweight	$46→$33
Aug 21, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$48
Jun 15, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$48
Jun 10, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$45
Apr 13, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$48
Mar 26, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$48
Mar 12, 2026	BTIG	Jeet Mukherjee	Assumes	Buy	$48
Dec 4, 2025	Oppenheimer	Matthew Biegler	Initiate	Outperform	$45
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Buy	$51
Nov 10, 2025	BTIG	Justin Zelin	Initiate	Buy	$50
Nov 5, 2025	Piper Sandler	Biren Amin	Initiate	Overweight	$48
Mar 27, 2025	JP Morgan	Brian Cheng	Initiate	Overweight	—

Analyst Ratings News

Ascentage Pharma Stock Could More Than Double: Analyst

William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.

Vandana Singh

PRO
William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Outperform rating.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46

Citigroup analyst Yigal Nochomovitz initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Buy rating and announces Price Target of $46.

Benzinga Newsdesk

PRO
Citizens Initiates Coverage On Ascentage Pharma Group with Market Outperform Rating, Announces Price Target of $35

Citizens analyst Silvan Turkcan initiates coverage on Ascentage Pharma Group (NASDAQ:AAPG) with a Market Outperform rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

JP Morgan analyst Brian Cheng maintains Ascentage Pharma Group (NASDAQ:AAPG) with a Overweight and lowers the price target from $46 to $33.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target

BTIG analyst Jeet Mukherjee reiterates Ascentage Pharma Group (NASDAQ:AAPG) with a Buy and maintains $48 price target.

Benzinga Newsdesk

Ascentage Pharma Group International

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ascentage Pharma Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Ascentage Pharma Stock Could More Than Double: Analyst

PRO
William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating

PRO
Citigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46

PRO
Citizens Initiates Coverage On Ascentage Pharma Group with Market Outperform Rating, Announces Price Target of $35

PRO
JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

PRO
BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target

People Also Watch

People Also Watch

Ascentage Pharma Group International

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Ascentage Pharma Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Ascentage Pharma Stock Could More Than Double: Analyst

PROWilliam Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating

PROCitigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46

PROCitizens Initiates Coverage On Ascentage Pharma Group with Market Outperform Rating, Announces Price Target of $35

PROJP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

PROBTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target

People Also Watch

People Also Watch

PRO
William Blair Initiates Coverage On Ascentage Pharma Group with Outperform Rating

PRO
Citigroup Initiates Coverage On Ascentage Pharma Group with Buy Rating, Announces Price Target of $46

PRO
Citizens Initiates Coverage On Ascentage Pharma Group with Market Outperform Rating, Announces Price Target of $35

PRO
JP Morgan Maintains Overweight on Ascentage Pharma Group, Lowers Price Target to $33

PRO
BTIG Reiterates Buy on Ascentage Pharma Group, Maintains $48 Price Target